Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The glycosaminoglycan (GAG) layer of the urothelium is a protective, mucinous coating on the inner surface of the bladder and urinary tract epithelium. It is composed of proteoglycans expressing heparan sulfate, chondroitin sulfate, and dermatan sulfate. This layer acts as a barrier against urine components, toxins, and pathogens, preventing their penetration into deeper bladder layers. Damage or deficiency of the GAG layer is implicated in conditions like interstitial cystitis/bladder pain syndrome, leading to increased permeability, inflammation, and pain. Therapies targeting the GAG layer aim to restore its integrity and function, often using exogenous GAGs like hyaluronic acid or chondroitin sulfate.
Restoration of the GAG layer, Replenishment of GAGs on the urothelial surface, Reduction of urothelial permeability
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosaminoglycan Layer of the Urothelium (GAG Layer).